High Prevalence of Hepatitis and Increasing Awareness Regarding Hepatitis to Augment Growth of Hepatitis Drugs Market
High prevalence of hepatitis is expected to propel growth of the global hepatitis drugs market. For instance, in May 2019, according to the study, ‘Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda’, published in May 2019, in BMC Infectious Diseases, the prevalence of hepatitis B surface antigen was 3.9% in the study population. Moreover, development of novel diagnostic tests is also expected to aid in growth of the market. For instance, in January 2019, LabCorp, along with its subsidiary Covance Inc., partnered with GENFIT, a biopharmaceutical company focused on R&D in liver diseases, for access to non-alcoholic steatohepatitis liver diagnostic test for the clinical research market.
Increasing
awareness regarding hepatitis is expected to offer lucrative growth
opportunities for players in the global hepatitis
drugs market. For instance, in May 2020, Echosens, a provider of
non-invasive diagnostic products and services for liver diagnosis, urged
increased vigilance around liver health during May 2020 Hepatitis Awareness
Month. Moreover, R&D in new therapies is also expected to aid in growth of
the market. For instance, in December 2020, Aligos Therapeutics, Inc. entered
into an Exclusive License and Research Collaboration Agreement with Merck,
under which Merck and Aligos will apply Aligos’ oligonucleotide platform
technology to discover, research, optimize and develop oligonucleotides
directed against a non-alcoholic steatohepatitis (NASH) target and up to one
additional target of interest in the cardiometabolic/fibrosis space.
Competitive Analysis
Major
players operating in the global hepatitis drugs market include, Merck & Co.
Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, Gilead
Sciences, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero
Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Major
players operating in the global hepatitis drugs market are focused on adopting
M&A strategies to enhance their market share. For instance, in December 2020,
Gilead Sciences signed a definitive agreement to acquire German biotechnology
company MYR for approximately US$ 1.4 billion in cash. With this deal, Gilead
will acquire First-in-Class entry inhibitor Hepcludex (bulevirtide) for the
treatment of chronic hepatitis delta virus (HDV), a severe form of viral
hepatitis.
Major
players operating in the global hepatitis drugs market are also focused on
adopting collaboration strategies to enhance their market share. For instance,
in January 2021, Gilead Sciences, Inc. collaborated with Vir Biotechnology,
Inc. to evaluate therapeutic combination strategies aimed at developing a
functional cure for chronic hepatitis B virus.
Comments
Post a Comment